PA
ORIC icon

Profund Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Profund Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$495K Sell
45,700
-5,819
-11% -$52.8K 0.01% 560
2026
Q1 		$653K Sell
51,519
-13,641
-21% -$155K 0.02% 466
2025
Q4 		$533K Buy
65,160
+46,440
+248% +$535K 0.02% 540
2025
Q3 		$225K Buy
+18,720
New +$197K 0.01% 909
2025
Q2 		– Sell
-16,469
Closed -$91.9K – 1033
2025
Q1 		$91.9K Buy
16,469
+5,651
+52% +$49.4K ﹤0.01% 958
2024
Q4 		$87.3K Sell
10,818
-2,684
-20% -$24.6K ﹤0.01% 1078
2024
Q3 		$138K Sell
13,502
-8,359
-38% -$82.6K 0.01% 1090
2024
Q2 		$155K Buy
21,861
+4,175
+24% +$37.4K 0.01% 1017
2024
Q1 		$243K Buy
+17,686
New +$210K 0.01% 970

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Profund Advisors's ORIC Position: Q2 2026 in Review

Profund Advisors reduced its Oric Pharmaceuticals (ORIC) stake by 11% in Q2 2026, selling an estimated $52.8K and leaving 45,700 shares worth $495K. The position accounts for 0.01% of the portfolio, ranked #560.

Profund Advisors first reported a position in ORIC in Q1 2024 and has held it in 9 quarters since. The position peaked at $653K in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Profund Advisors held 45,700 shares of Oric Pharmaceuticals worth $495K as of Q2 2026.
  • Profund Advisors sold 5,819 Oric Pharmaceuticals shares in Q2 2026, an estimated $52.8K.
  • Oric Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #560 holding.
  • Profund Advisors first reported a position in Oric Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Profund Advisors's Oric Pharmaceuticals position peaked at $653K in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.